Enhanced vascular VCAM-1+ immune-reactivity in response to SAA is indicative of endothelial dysfunction and this may manifest as decreased bioavailability/bioactivity of vasodilating nitric oxide (NO). The gene discussed is VCAM1; the disease is endothelial dysfunction.